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During the last decades, mortality from acute myocardial infarction has been dramati-
cally reduced. However, the incidence of post-infarction heart failure is still increas-
ing. Cardioprotection by ischaemic conditioning had been discovered more than
three decades ago. Its clinical translation, however, is still an unmet need. This is
mainly due to the disrupted cardioprotective signalling pathways in the presence of
different cardiovascular risk factors, co-morbidities and the medication being taken.
Sensory neuropathy is one of the co-morbidities that has been shown to interfere
with cardioprotection. In the present review, we summarize the diverse aetiology of
sensory neuropathies and the mechanisms by which these neuropathies may inter-
fere with ischaemic heart disease and cardioprotective signalling. Finally, we suggest
future therapeutic options targeting both ischaemic heart and sensory neuropathy
simultaneously.
Abbreviations: AMI, acute myocardial infarction; CAN, cardiovascular autonomic neuropathy; CMT, Charcot–Marie–Tooth disease; FD, familial dysautonomia; HFpEF, heart failure with
preserved ejection fraction; HSANs, hereditary sensory and autonomic neuropathies; IKBKAP, in B-cells kinase complex-associated protein; PDE5, PDE type 5; RA, rheumatoid arthritis; RTX,
resiniferatoxin; SERCA2a, sarco-endoplasmic reticulum Ca2+-ATPase type 2a; SLE, systemic lupus erythematosus; SP, substance P; SST, somatostatin; STZ, streptozotocin; TH, tyrosine-
hydroxylase; TRP, transient receptor potential; TRPA1, transient receptor potential ankyrin 1; TRPV1, transient receptor potential vanilloid type 1.
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1 | INTRODUCTION—
CARDIOPROTECTION AND SENSORY
NERVES IN THE HEART
The acute care of myocardial infarction has been dramatically
improved by the introduction of percutaneous coronary interven-
tion and stenting thereby decreasing its early mortality. However,
the incidence of chronic postinfarction heart failure is rising faster
than previously expected (Lam, Donal, Kraigher-Krainer, &
Vasan, 2011). Cardioprotective interventions such as local and
remote ischaemic and pharmacological pre-conditioning, post-condi-
tioning, and per-conditioning have been discovered and extensively
studied in the last three decades (Ferdinandy, Hausenloy, Heusch,
Baxter, & Schulz, 2014). However, their clinical translation has been
failed so far, most probably due to several confounding factors
including co-morbidities, co-medications and variable genetic back-
ground (see for a recent extensive review Hausenloy et al., 2017).
Among cardiovascular co-morbidity states such as hyperlipidaemia,
diabetes mellitus and confounders such as aging or sex differences
(see for reviews Ferdinandy et al., 2014; Ferdinandy, Szilvassy, &
Baxter, 1998), sensory neuropathy has also been recognized as a
confounding factor. Nevertheless, only a small amount of preclinical
and clinical data are available on the influence of sensory
neuropathy to ischaemic heart disease and cardioprotection (Ieda &
Fukuda, 2009).
The innervation of the heart is composed of intricate feedback
loops of autonomic nervous system consisting of intrinsic cardiac gang-
lia, extracardiac intrathoracic ganglia, the spinal cord and areas of the
CNS (Ardell et al., 2016). The effector machinery involves autonomic
neurons of the sympathetic and parasympathetic nervous systems, as
well as non-adrenergic–non-cholinergic (NANC) sensory nerves acti-
vated by hypoxia, ROS and increased concentrations of H+ and K+,
leading to the release of neuropeptide transmitters (Franco-Cereceda &
Lundberg, 1988; see Figure 1). Cardiac sensory nerves can be localized
separately having their own separate afferent soma inside intrinsic
cardiac ganglionated plexi, but most of them are coupled to autonomic
nerves including the parasympathetic vagal and sympathetic efferents
(Ardell et al., 2016). In the clinical settings, pathologies impairing sen-
sory nerves frequently also affect autonomic nerves, thereby combin-
ing the symptoms derived from both sensory and/or autonomic
neuropathies, which lead to complex clinical presentation of the symp-
toms. Even in cases of primary, hereditary neuropathies (see below),
neural injury shows a mixture of sensory and autonomic dysfunctions.
Only preclinical models (e.g. capsaicin or resiniferatoxin (RTX)-induced
desensitization) are appropriate to clearly describe the cardiac effects
of selective sensory neuropathy. Sensory neuropathy may affect all
F IGURE 1 Sensory innervation of the
heart. We focused on cardiac sensory
nerves, but there are several other types
of cardiac nerves and neurons (see in
detail in the text of Section 2). Cardiac
sensory fibres are coupled to both
sympathetic and parasympathetic (vagus)
nerves and can be separated from the
autonomic nervous system. The capsaicin-
sensitive sensory nerve terminals are
activated and sensitized by a variety of
mediators produced by ischaemia,
inflammation and tissue damage, and
mediate sensory input pain and reflexes
(classical afferent function). β1R, β1-
adrenoceptor; DRG, dorsal root ganglion;
PGs, prostaglandins; M2R,M2 receptor;
TRPA1, transient receptor potential
ankyrin 1; TRPV1, transient receptor
potential vanilloid-1
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types of sensory neurons involved in myocardial regulation and
therefore, in most pathologies affecting the complex cardiac sensory
machinery, it is hard to distinguish between the localization of the
lesion/s and the degree of neural damage.
Although sensory and autonomic neuropathies are important
common contributors to the development of ischaemic heart disease,
they are still not the focus of cardiovascular research. However, better
understanding of these mechanisms may help to develop effective
cardioprotective therapies. In this review, we collected the available
data to summarize the diverse causes of sensory neuropathy and its
contribution to cardiac pathology. We systematically evaluate preclini-
cal models used to investigate the cardiac consequences of sensory
neuropathy, as well as clinical data on concomitant occurrence of sen-
sory neuropathies and cardiac pathologies. Furthermore, we summa-
rize the mechanisms and effects of sensory neuropathy on myocardial
ischaemia and cardioprotection. Finally, we highlight the therapeutic
perspectives to achieve cardioprotection in the presence of sensory
neuropathy.
2 | PHYSIOLOGICAL ROLE OF CARDIAC
SENSORY NERVES
The complexity of the functional role of sensory nerves innervating
the heart has only recently been recognized. Classical studies have
revealed the anatomy and functional significance of cardiac sensory
nerves in the mechanisms of fundamental reflexes regulating heart
function (Dawes & Comroe, 1954). Cardiac innervation includes a
complex multiple-levelled regulatory system consisting of feedback
and feed-forward neuronal circuits. Intrinsic cardiac ganglion plexus
contains sympathetic and parasympathetic postganglionic efferent
neurons, local circuit and afferent neurons, while extracardiac intra-
thoracic ganglia possess afferent and local circuit neuron as well as
sympathetic postganglionic efferents. Neurons in both circuits form
regulatory loops with higher centres (e.g. spinal cord, medulla
oblongata and hypothalamus) under cortical neuronal control (Ardell
et al., 2016). Cardiac afferents are coupled to both sympathetic and
parasympathetic (vagus) efferent nerves and can also be separated
from the autonomic nervous system (Figure 1). Cardiac afferent
nerves, which can be excited by capsaicin, were first identified in
investigations into the mechanisms of action of cardiorespiratory
chemoreflexes. These studies showed that a substantial population of
chemosensitive afferent nerves that convey these reflexes are acti-
vated by capsaicin (Porszasz, Gyorgy, & Porszasz-Gibiszer, 1955). The
characteristic cardiorespiratory chemoreflex evoked by capsaicin con-
sisting of bradycardia, hypotension and apnoea could be inhibited by
prior perineural treatment of the cervical vagal nerves with capsaicin,
resulting in the selective interference of the function of capsaicin- but
not phenylbiguanide-sensitive C-fibres (Jancso & Such, 1983).
Chemosensitive afferents sense cardiac pain and mediate the cardio-
genic sympathetic reflex (Pan & Chen, 2004).
Capsaicin is the pungent component of peppers that is able to
selectively activate and/or disrupt an important subpopulation of
sensory neurons, thinly myelinated Aδ and/or unmyelinated C fibres
(Jancsó, 1968). Systemic administration of high-dose capsaicin disrupt
these primary sensory neurons in a rather more complex way. In new-
born animals, systemic administration of high-doses of capsaicin
results in a selective loss of small, type B nociceptive primary sensory
neurons (Jancso, Kiraly, & Jancso-Gabor, 1977), but in adults, it pro-
duces long-term desensitization and functional impairment of these
neurons. Quantitative electron microscopic examination revealed a
significant and selective loss of about 40% of unmyelinated afferent
axons in peripheral sensory nerves (Jancso, Kiraly, Joo, Such, &
Nagy, 1985) and up to 94% in spinal dorsal roots (Nagy, Iversen,
Goedert, Chapman, & Hunt, 1983). Importantly, autonomic nerve
fibres are not affected by capsaicin treatment (Jancsó, Such, Király,
Nagy, & Bujdosó, 1985). In contrast to the comparatively moderate
loss of C sensory fibre number, profound reduction was detected in
the levels of neuropeptide transmitters specific to these nociceptive
primary sensory neurons (Gamse, Lackner, Gamse, & Leeman, 1981;
Jancso & Knyihar, 1975).
There is ample evidence that the effects of capsaicin are being
mediated through the activation of the transient receptor potential
vanilloid type 1 receptor (TRPV1) also known as the vanilloid recep-
tor 1 or the capsaicin receptor (Caterina et al., 1997) expressed in
chemosensitive primary sensory neurons. TRPV1 receptor physiolog-
ically can be activated and/or sensitized by several stimuli, such as
H+, K+, bradykinin, ROS and prostaglandins (Nagy, Santha, Jancso, &
Urban, 2004; Randhawa & Jaggi, 2015; Figures 1 and 2). Another
TRP receptor, transient receptor potential ankyrin 1 (TRPA1) is
expressed and co-localized with TRPV1 receptors in the cardiac mus-
cle (Andrei, Sinharoy, Bratz, & Damron, 2016). TRPA1 is also present
on vascular smooth muscle cells and sensory nerves in the heart,
which are also activated by ROS, Ca2+ and prostaglandins (Wang, Ye,
et al., 2019; Figures 1 and 2). Anatomical and functional evidence
indicate that capsaicin-sensitive primary afferent neurons of both
spinal (thoracic dorsal root ganglia) and vagal (nodose ganglion) ori-
gins innervate the heart (Ferdinandy et al., 1997; Jancso &
Such, 1983; Pan & Chen, 2004).
A significant proportion of chemosensitive afferents expressing
the TRPV1 receptor are peptidergic, which are involved in more func-
tions than just sensory input such as pain and reflex regulation of the
cardiorespiratory system. Sensory neuropeptides are released from
these fibres in response to activation not only experimentally by cap-
saicin and exogenous vanilloid, but also by a broad range of inflamma-
tory stimuli and tissue irritants which exert important effector
functions on the heart (Jancsó, 1968; Jancso, Kiraly, Such, Joo, &
Nagy, 1987). CGRP, substance P (SP) and pituitary adenylate cyclase-
activating polypeptide (PACAP-38) induce vasodilatation, plasma pro-
tein activation and mainly immune and inflammatory cell activation in
the innervated area, collectively called neurogenic inflammation
(Figure 2; Holzer, 1988). Meanwhile besides the pro-inflammatory
peptides, inhibitory mediators, such as somatostatin, galanin and opi-
oid peptides are also released from the same capsaicin-sensitive sen-
sory nerves in response to activation, which have anti-oedema, anti-
inflammatory, analgesic and cytoprotective actions when entering the
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systemic circulation, even at distant parts of the body (Holzer, 1988;
Jancso et al., 1987; Szolcsanyi, Pinter, Helyes, & Petho, 2011). Pitui-
tary adenylate cyclase-activating polypeptide (Harmar et al., 2012)
and CGRP (Li & Peng, 2002) are interesting as they are multifunctional
peptides. They have strong vasodilating actions contributing to the
vascular components of the inflammatory response, but also have a
potent inhibitor action on the cellular inflammatory mechanisms and
direct cytoprotective actions on the cardiomyocytes (Figure 2).
3 | MOLECULAR CHANGES IN THE
MYOCARDIUM IN THE PRESENCE OF
CAPSAICIN-INDUCED SENSORY
NEUROPATHY
A limited number of preclinical papers are available in the literature
which discuss the effect of sensory neuropathy on cardiac cell signal-
ling. Most of the data are restricted to the sensory neuropathy evoked
by systemic capsaicin treatment-induced sensory desensitization.
Therefore, in the following section, we will present data from papers
using preclinical model of capsaicin-induced sensory neuropathy.
More than a decade ago, Zvara et al. showed cardiac functional
alterations and gene expression changes in rat hearts 7 days after
the induction of sensory neuropathy by systemic capsaicin treat-
ment, using DNA microarray technique. Capsaicin-induced sensory
neuropathy resulted in cardiac dysfunction characterized by eleva-
tion of left ventricular end-diastolic pressure which led to significant
up-regulation of 47 and significant down-regulation of 33 genes
out of 6400 genes available on the microarray. Sensory neuropathy
has been shown to influence a variety of neuronal and non-
neuronal genes in the heart including vanilloid receptor-1 TRP pro-
tein, GABA receptor rho-3 subunit, cytochrome P450 subfamily
2A, polypeptide 1 (CYP2A1), 5-HT3B receptor, NK2 receptor,
matrix metalloproteinase-13, farnesyl-transferase, Apo B apolipo-
protein, leptin and endothelial NOS (Zvara et al., 2006).
Bencsik et al. found that sensory neuropathy (chemo-denerva-
tion) induced by 7 days of capsaicin treatment decreased the cardiac
NO availability via decreased activity of Ca2+-dependent NOS
isoforms (endothelial NOS and nNOS) and increased SOD activity
thereby lead to decreased basal ONOO− formation and a reduction of
S-nitrosylation of sarco-endoplasmic reticulum Ca-ATPase type 2a
(SERCA2a), which caused impaired myocardial relaxation in the rat
F IGURE 2 Sensory neuropeptides released
from these activated fibres exert important
functions on the heart both locally (local efferent
function) and via the bloodstream (systemic
efferent function). CGRP, substance P and
PACAP induce vasodilatation, plasma protein
activation, and immune cell activation in the
innervated area collectively called neurogenic
inflammation, while inhibitory mediators, such as
SST and PACAP, also released from the same
fibres exert anti-oedema, anti-inflammatory and
analgesic actions after getting into the systemic
circulation even at distant parts of the body.
PACAP and CGRP are multi-functional peptides;
they are potent vasodilators but inhibit
inflammatory cells and have cytoprotective
actions. The cardioprotective role of the
capsaicin-sensitive sensory nerves is likely to be
related to the protective neuropeptides, but the
mechanism of action needs further
investigations. PACAP, pituitary adenylate
cyclase-activating polypeptide; SP, substance P;
SST, somatostatin; TRPA1, transient receptor
potential ankyrin 1; TRPV1, transient receptor
potential vanilloid-1
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heart. The gene expression pattern of the three different isoforms of
NOS in the heart were also examined by real-time quantitative PCR.
Endothelial NOS (eNOS) was significantly down-regulated due to
capsaicin-desensitization. However, the expression of neuronal and
inducible NOS isoforms was unaffected (Bencsik et al., 2008).
A recent animal study of capsaicin-induced sensory neuropathy
revealed microRNA changes in the rat heart after 7 days of treatment
(Bencsik et al., 2019). Echocardiographic data showed a moderate dia-
stolic dysfunction in sensory neuropathy group and several microRNA
showed altered expression. Out of 711 miRNAs represented on the
miRNA microarray, the expression of 257 miRNAs was detectable,
from which miR-344b, miR-466b miR-98, let-7a, miR-1, miR-206 and
miR-34b showed down-regulation and miR-181a was up-regulated
due to sensory neuropathy. The altered miRNAs were selected for an
unbiased bioinformatic miRNA-target network analysis, which
predicted several target genes including insulin-like growth factor 1,
solute carrier family 2, facilitated glucose transporter member 12,
eukaryotic translation initiation factor 4e and unc-51 like autophagy
activating kinase 2, which were validated as potentially contributing
factors to cardiac diastolic dysfunction induced by sensory neuropa-
thy (Bencsik et al., 2019).
4 | THE EFFECTS OF SENSORY
NEUROPATHY ON MYOCARDIAL
ISCHAEMIA/REPERFUSION INJURY AND
INFARCTION
The number of available published papers in this special cardiovascu-
lar field is quite limited. The first report for the effects of sensory neu-
ropathy during the course of myocardial infarction was published by
Nesto and colleagues. They showed that diabetes-induced sensory
neuropathy may contribute to asymptomatic myocardial infarction,
probably due to lack of pain sensation as a result of injured sensory
nerves (Nesto & Phillips, 1986). Subsequently, several publications
confirmed the potential influence of diabetes-induced sensory neu-
ropathy in asymptomatic or silent ischaemia by enrolling high number
of acute myocardial infarction (AMI) or coronary artery disease
patients (Elliott et al., 2019). The first preclinical characterization of
experimental acute myocardial ischaemia/reperfusion injury ex vivo
after in vivo capsaicin-induced sensory neuropathy was published in
1997 by Ferdinandy et al. The authors did not observe significant
changes in ischaemia/reperfusion injury but a loss of pre-condition-
ing-induced cardioprotection (see next chapter). In another in vivo
study of myocardial infarction in the presence of capsaicin-sensitive
sensory nerve degeneration (Zhang, Guo, Wang, & Wu, 2012), the
authors used a rat model of capsaicin-sensitive sensory desensitiza-
tion induced by single subcutaneous capsaicin injection within the
first 48 hr after birth. Selective desensitization of capsaicin-sensitive
nerves was validated by a significant deterioration in tail flick test in
the capsaicin-treated group of rats at12 weeks of age before con-
ducting permanent coronary ligation. They found that infarct size was
significantly increased by sensory desensitization 6 hr after the
induction of coronary ligation. Furthermore, their finding was further
supported by the increased troponin I level and enhanced apoptosis
shown by elevated caspase-3 levels in the desensitized group (Zhang
et al., 2012). Earlier studies using systemic capsaicin pretreatment
indicated that chemosensitive afferent nerves confer cardioprotective
effects since prior to chemo-denervation by capsaicin impaired post-
ischaemic recovery was shown in isolated rat hearts (Ustinova,
Bergren, & Schultz, 1995) and an increase in the size of the myocardial
infarction was found in an in vivo porcine model of acute myocardial
infarction (AMI; Kallner, 1998). However, in the above-mentioned
studies, the presence of sensory neuropathy was not verified. The car-
dioprotective effect conferred by capsaicin-sensitive afferents
appeared to be mediated through activation of the TRPV1 receptor
which in turn induces release of substance P and CGRP from sensory
nerves. The role of the TRPV1 receptor in cardioprotection was
supported by the finding that post-ischaemic recovery was impaired
in TRPV1 knockout mice (Wang & Wang, 2005). Furthermore, admin-
istration of an endogenous vanilloid, N-oleoyl dopamine, protected
the ex vivo isolated mouse heart from ischaemia–reperfusion injury
by activating the TRPV1 receptor (Zhong & Wang, 2008).
In contrast, most recently, selective chemical ablation of TRPV1
positive neurons in the stellate ganglion by intra-ganglionic injection
of resiniferatoxin has been shown to decrease the incidence of severe
ventricular arrhythmias in dogs subjected to 60-min coronary ligation
(Zhou et al., 2019). This study suggests a pro-arrhythmic role of
TRPV1 positive neurons in the sympathetic nervous system innervat-
ing the heart.
5 | CARDIOPROTECTION IN THE
PRESENCE OF SENSORY NEUROPATHY
Since neuropathy manifests in the clinical scenario in a complex man-
ner, it is hard to separately characterize the sensory neuropathy com-
ponents of a pathology. Human data are mostly related to different
polyneuropathy conditions or cardiac autonomic neuropathy. How-
ever, the results of some animal models specifically mimicking sensory
neuropathy revealed a role for sensory nerves in several mechanisms
of cardioprotection. An excellent review was recently published about
the function of intact cardiac innervation in cardioprotection by
remote ischaemic conditioning (Hausenloy et al., 2019), focusing on
diabetic neuropathy in remote conditioning. Therefore, in the present
review, we have focused on myocardial ischaemia/reperfusion injury
and cardioprotection in the presence of a wide range of co-morbid-
ities, where the deterioration of sensory neural system has been
shown to be involved in these pathologies. Cardioprotection (local
and remote) can be classified at three different levels which are stimu-
lus, transfer and target levels (Kleinbongard, Skyschally, &
Heusch, 2017). Both sensory and autonomic nerves might be involved
in all of these three levels. The complex actions of sensory and auto-
nomic nerves involving higher CNS regions, such as the spinal cord or
brainstem, have been reviewed in detail (Kleinbongard et al., 2017).
However, the current knowledge on the specific contribution of
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sensory nerves to cardioprotection is not sufficient precise to classify
their diverse actions at these three levels of cardioprotection.
More than two decades ago, we showed that systemic desensiti-
zation of the capsaicin-sensitive afferents by high-dose capsaicin pre-
treatment in rats abolished the protective effect of pre-conditioning
evoked by rapid ventricular pacing in isolated hearts with coronary
occlusion and reperfusion (Ferdinandy et al., 1997). Several
publications reported that ischaemic pre-conditioning-induced
cardioprotection is attenuated in animal models of Type 2 diabetes,
when diabetic neuropathy is present (extensively reviewed elsewhere,
Whittington, Babu, Mocanu, Yellon, & Hausenloy, 2012). Further-
more, the cardioprotective effect of patients' serum taken after cycles
of BP cuff inflation/deflation of the arm was only detected in cases of
healthy subjects and diabetics without neuropathic complications,
when these serum samples were applied to the isolated rabbit hearts
with ischaemia–reperfusion injury (Jensen, Stottrup, Kristiansen, &
Botker, 2012). The critical role of TRPV1 receptors in ischaemic pre-
conditioning was also demonstrated in experiments showing that
deletion of the TRPV1 gene impaired pre-conditioning-induced
cardioprotection, the protection being mediated by the release of sub-
stance P and CGRP from sensory nerves (Zhong & Wang, 2008). The
pivotal role of TRPV1 receptor activation is strongly supported by the
results that TRPV1 knockout animals show impaired post-ischaemic
recovery (Wang & Wang, 2005). This combined experimental data
unequivocally indicates that activation of cardiac capsaicin-sensitive
afferents confer potent cardioprotective effect on the myocardium,
through the release of the above neuropeptides. Furthermore, nerve
growth factor has been shown to be critical for up-regulation of
TRPV1 receptors in primary sensory neurons from adult rats (Winter,
Forbes, Sternberg, & Lindsay, 1988), in particular those containing
CGRP. The role of TRPV1 receptor in cardioprotection was supported
by the finding that reperfusion injury of diabetic mice hearts was
attenuated after nerve growth factor administration up-regulated
TRPV1 receptor expression (Zheng et al., 2015). Although these
results clearly demonstrate the critical role of capsaicin-sensitive
afferent nerves and their TRPV1 receptors in cardioprotection against
ischaemic injury, a potential role of TRPV1 receptors expressed by rat
cardiomyocytes (Qi et al., 2015; Zvara et al., 2006) has not been con-
sidered. Data about the involvement of TRPA1 channels in
cardioprotection are controversial. Activation of TRPA1 by optovin
led to enhanced survival rate of cardiac myocytes subjected to simu-
lated ischaemia and reperfusion (Lu, Piplani, McAllister, Hurt, &
Gross, 2016). However, in vivo coronary occlusion/reperfusion in
TRPA1 knockout mice resulted in a reduction of myocardial infarct
size (Conklin et al., 2019).
Both substance P and CGRP have been shown to participate in
sensory nerve-mediated cardioprotection. Myocardial ischaemia is
associated with a decrease in the cardiac level of substance P and in
turn, administration of substance P reduced ischaemic myocardial
damage in Langendorff-perfused hearts of rats subjected to
systemic capsaicin pretreatment (Ustinova et al., 1995). Experimental
evidence indicates that CGRP released from capsaicin-sensitive cardiac
afferents also induces cardioprotection against ischaemic myocardial
damage in pig and rat acute myocardial injury models (Kallner, 1998; Li,
Xiao, Peng, & Deng, 1996). The role of CGRP and NO in the pacing-
induced and capsaicin-sensitive nerve-mediated cardioprotection has
been previously demonstrated (Ferdinandy, 2009; Ferdinandy
et al., 1997). Cardioprotective effect of remote pre-conditioning
induced by direct stimulation of sensory nerves is mediated by the
release of cardioprotective humoral factors, including sensory
neuropeptides and NO. This humoral response was abolished by
topical DMSO treatment damaging the sensory nerves and also by
intra-arterial NO-donor treatment applied prior to stimulating the
sensory nerves with topical capsaicin treatment in an in vivo remote
ischaemia/reperfusion rabbit model (Redington et al., 2012).
Further evidence for the neural component of remote ischaemic pre-
conditioning is that hexamethonium, a selective ganglionic blocker, can
abolish the cardioprotective protective effects of short mesenteric
artery occlusion-triggered adenosine release in an in vivo rat model of
acute myocardial infarction (Liem, Verdouw, Ploeg, Kazim, &
Duncker, 2002). However, the latter study has not investigated the role
of sensory nerves in its remote ischaemic pre-conditioning model.
Recently, it has been reported that somas of sensory neurones may
release exosomes (a type of extracellular vesicles) containing micro-
RNAs and other factors by which they can regulate cell–cell communi-
cation (Simeoli et al., 2017).
6 | CO-MORBIDITIES SIMULTANEOUSLY
AFFECTING THE SENSORY NERVES AND THE
HEART
In this section, we describe several disease states leading to sensory
neuropathy and ischaemic or other cardiac pathologies simulta-
neously. We summarize the main features of each disease, provide
human data in relation to sensory neuropathy and cardiac symptoms
and finally, show preclinical research models for sensory neuropathy
of different aetiologies (see also Table 1). The available animal models
are mainly rodent models with several limitations, but they can be
suitable to investigate how sensory nerves influence the ischaemic
myocardium. Large animal models for neuropathies are scarce in the
literature, but some canine models for primary sensory neuropathies
have recently been developed (Correard et al., 2019).
6.1 | Primary neuropathies: Hereditary disorders
There are several types of genetic disorders, which lead to sensory
neuropathy and may be related to cardiovascular symptoms.
Charcot–Marie–Tooth (CMT) disease is the most frequently
occurring hereditary sensory peripheral polyneuropathy caused by
mutations affecting mainly myelinated Schwann cells (CMT1) or it is
characterized by axonal degeneration (CMT2; Timmerman,
Strickland, & Zuchner, 2014). In the extensive literature on this dis-
ease only a few case reports refer cardiac effects. In a recent paper,
regarding CMT disease, a novel cardiomyopathy condition, non-
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compaction cardiomyopathy (or ventricular hypertrabeculation), was
described (Eltawansy, Bakos, & Checton, 2015), which is accompanied
with high incidence of arrhythmias and embolic complications. Given
the numerous mutations and genes associated with CMT, there are
several animal models under development. One of them the CMT1A,
which represents 70–80% of all CMT1 cases, is caused by a duplica-
tion in peripheral myelin protein 22 (PMP22) gene (Inoue et al., 2001).
However, cardiac involvements have not been investigated in these
models yet.
Other, less common hereditary sensory and autonomic neuropa-
thies (HSANs) are classified into six major types (I–VI) and several fur-
ther subtypes (Lynch-Godrei, De Repentigny, Gagnon, Trung, &
Kothary, 2018). Solid evidence of cardiac involvement in these dis-
eases is lacking with one exception, familial dysautonomia (FD, HSAN
III). This is a rare neurological disorder caused by a splice mutation in
the inhibitor of κ light polypeptide gene enhancer in B-cells kinase
complex-associated protein (IKBKAP) gene. Cardiovascular instability
is the most striking feature of FD, which is characterized by postural
hypotension and episodic hypertension, as well as tachycardia and
decreased cardiac sympathetic innervation (Goldstein, Eldadah,
Sharabi, & Axelrod, 2008). FD patients have an increased index of QT
variability and decreased heart rate variability which is predictive of
mortality. Further, multiple conventional and advanced electrocardio-
graphic abnormalities suggest structural heart disease. Modelling of
FD disease (HSAN III) in mouse has been carried out by several
research groups. The development of a suitable mouse model was
challenging due to the differences in man and mouse gene splicing
and the impact of the disease-causing T to C transition (Rubin &
Anderson, 2017). However, during the development of these models,
many promising therapeutic strategies and drug candidates have been
identified (Yoshida et al., 2015). First attempts to generate a human-
ized FD mouse using bacterial artificial chromosome to deliver the full
human IKBKAP gene containing the mutation (IVS20 + T! C) into the
mouse genome were unsuccessful, because the created mouse model
did not manifest any FD symptoms and was phenotypically normal
(Hims et al., 2007). Using knockout approach was also ineffective,
because the complete deletion of mouse Ikbkap results in early embry-
onic lethality (Chen et al., 2009). Dietrich et al. created two lines of
mice carrying a conditional inactivation Ikbkap allele, Ikbkapflox/flox and
IkbkapΔ20/flox. Both lines of mice manifested features of FD, including
severe reduction in nociceptive (trkA/CGRP positive) neurons at late
gestation, small stature, ataxic gait, loss of fungiform papillae,
kyphosis or kyphoscoliosis (Dietrich, Alli, Shanmugasundaram, &
Dragatsis, 2012). In the FD mouse models, in dorsal root ganglia mito-
chondria were depolarized and fragmented and ROS levels were sig-
nificantly increased, which could validate the presence of neuropathy.
Mitochondrial dysfunction is a major factor mediating the death of
Ikbkap−/− neurons (Ohlen, Russell, Brownstein, & Lefcort, 2017). In
the absence of Ikbkap, cardiac innervation is reduced, but other char-
acteristic cardiac symptoms, which were observed in humans have
not been investigated in these animal models.
Hereditary transthyretin amyloidosis (hATTR) due to the deposi-
tion of insoluble amyloid fibrils leads to sensory and autonomic
neuropathies with simultaneous cardiac complications characterized
by refractory cardiomyopathy, which develops due to left ventricular
amyloid deposits (Adams, Koike, Slama, & Coelho, 2019). Over
130 mutations may cause hATTR that manifest as combined cardiac
and neurologic symptoms. In a most recent retrospective clinical study
(Lai et al., 2019), heart failure was found to be the major cause of
death in hATTR patients. The authors revealed that the most sensitive
prognostic marker for cardiac involvement were global longitudinal
strain and mitral valve E/A ratio during echocardiographic analysis.
Similarly, to hATTR, there are other types of amyloid deposits, for
example gelsolin amyloidosis (also known as familial amyloidosis Finn-
ish type), which may simultaneously affect the heart and peripheral
nervous system, thereby leading to ventricular arrhythmias or atrio-
ventricular blocks. However, these consequences derive from multi-
organ amyloid accumulation rather than directly from amyloid-
induced damage of the autonomic or sensory nerves (Lehmonen,
Kaasalainen, Atula, Mustonen, & Holmstrom, 2019). The attempt to
create a successful animal model for hATTR started around 30 years
ago (Shimada et al., 1989) and even the ideal model that replicates all
human characteristics of the disease is still has not been obtained.
In 2010, Santos Fernandes, and Saraiva created a mouse model
expressing human transthyretin V30M mutation in a heat shock tran-
scription factor 1 null background, which has been used several times.
Santos et al. validated the chronic neurodegeneration in dorsal root
ganglia and sciatic nerves, but not early pain symptoms of hATTR, and
there was no data on cardiac involvement.
Friedreich's ataxia (FRDA) is a progressive neurodegenerative dis-
ease affecting mainly sensory neurons and nerves of the spinal cord
and thereby leads to severe ataxia, nystagmus and other cerebellar
symptoms. FRDA caused by an autosomal recessive mutation, which
leads to a GAA repeat expansion in intron 1 in the gene of the mito-
chondrial protein frataxin (Durr et al., 1996). FRDA also involves car-
diac disturbances such as increased LV wall thickness, reduced
chamber size and finally hypertrophic cardiomyopathy leading to heart
failure with preserved ejection fraction (HFpEF; Peverill, Donelan,
Corben, & Delatycki, 2018). Impaired myocardial perfusion in an
FRDA patient was described to be the result of microvascular abnor-
mality without epicardial coronary artery disease (Raman, Dickerson, &
Al-Dahhak, 2008). The occurrence of atrial fibrillation and ventricular
tachyarrhythmias is also common, which eventually increases cardiac
mortality (Zipse & Aleong, 2016). Association between acute myocar-
dial infarction and FRDA disease was found only in two case reports
(Sharma, Kiyokawa, Kim, Lee, & Kasuya, 2002). In 2001, Puccio et al.
were the first to create mutant mice through conditional gene
targeting (frataxin-deficient line) to evaluate treatment strategies for
FRDA. When frataxin gene is ablated in brain (neural tissues) and
heart, the mice demonstrate a severe disorganization of
cardiomyocytes, dilated cardiomyopathy, very short life span, ataxia
and loss of proprioception in behavioural studies, such as the rotarod.
Fabry or Anderson–Fabry disease is an X-chromosome-linked
hereditary lipid storage disease caused by various mutations of the
human GLA gene resulting in a decreased expression and activity
of the lysosomal α-galactosidase A (AGAL). Reduced enzymatic
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activity affects the degradation of the complex glycosphingolipid/
globotriaosylceramide (also known as Gb3 or CD77). Prevailing
effect of the impaired GSL catabolism is peripheral neuropathy
affecting neurons of autonomic ganglia and Aδ- and C-fibre sen-
sory ganglion cells (see for review Politei et al., 2016). Small fibre
neuropathy is characterized by pathological pain, impaired
thermosensation and acroparaesthesia, as well as autonomic symp-
toms of reduced sweating (hypohydrosis), reduced heart rate vari-
ability and orthostatic hypotension (Politei et al., 2016). Cardiac
manifestations of the disease include concentric left ventricular
hypertrophy leading ultimately to cardiac failure, conduction block
and ventricular arrhythmias or tachycardia (Baig et al., 2019), which
are mainly accounted for by direct impairments of cardiomyocytes
and coronary blood vessels. Recently, an early impairment of car-
diac innervation has been demonstrated by SPECT studies showing
gradual elimination of the sympathetic nerves innervating the left
ventricle in patients affected by Fabry disease (Imbriaco
et al., 2017). Similar abnormalities in sensory and autonomic func-
tions have been observed in an animal model of the disease
(Hofmann et al., 2018).
6.2 | Secondary neuropathies: Diabetes
Diabetes mellitus is likely the most frequent metabolic disease that
affects peripheral nervous system, especially sensory nerves. Diabetic
patients with sensorimotor neuropathy develop clear signs of diffuse
autonomic impairment affecting both the visceral sensory system and
cardiac autonomic nervous systems (Softeland et al., 2014). Diabetes-
associated damage of sensory nerves occurs simultaneously with dam-
age of autonomic nerves. Therefore, in this chapter, we discuss the
presentation of cardiovascular autonomic neuropathy (CAN) instead
of sensory neuropathy in diabetes mellitus. Cardiovascular autonomic
neuropathy damages autonomic nerve fibres causing abnormalities
mainly in heart rate and vascular dynamics (Agashe & Petak, 2018).
Cardiovascular autonomic neuropathy is a common complication
of diabetes resulting in reduced ejection fraction and diastolic cardio-
myopathy (Voulgari, Papadogiannis, & Tentolouris, 2010). It has been
shown (Chessa et al., 2002) that a decrease in heart rate variability
(HRV), which is an indicator of the reduced influence of parasympa-
thetic efferent activity on the heart, is one of the earliest signs of car-
diovascular autonomic neuropathy and is correlated with the duration
of hyperglycaemia and the degree of glycaemic control in children
with insulin dependent diabetes. Type 1 diabetes can cause left ven-
tricular sympathetic dysinnervation with proximal hyperinnervation
resulting in severe myocardial perfusion retention and left ventricular
dysfunction (Stevens et al., 1998). Hypoglycaemia itself can induce
QT interval prolongation, which is one of the major predictor of
arrhythmias originated from both sympatho-adrenal activation and a
lowered serum potassium level (Lee et al., 2004). Resting tachycardia
is not a specific sign of CAN, however increased heart rate enhanced
all-causes of mortality in Type 2 diabetic patients, as shown by a
recent meta-analysis (Aune et al., 2017). Diagnosis of cardiovascular
autonomic neuropathy is still not conclusive, as some diagnostic
symptoms are not highly specific for cardiovascular autonomic neu-
ropathy (Spallone, 2019). Cardiovascular signs like tachycardia, QT
prolongation and orthostatic hypotension, frequently occur in associa-
tion with cardiovascular autonomic neuropathy and therefore suggest
cardiovascular monitoring in diabetic patents (Spallone et al., 2011).
Toronto consensus recommended the use of cardiovascular auto-
nomic reflex tests (Valsalva manoeuvre, heart rate response to deep
breathing and standing, and orthostatic hypotension tests) for diagno-
sis of cardiovascular autonomic neuropathy (Spallone et al., 2011).
Several mechanisms have been revealed from the abundant num-
ber of animal models which could be link cardiovascular autonomic
neuropathy and worsened cardiac function. However, here we pre-
sent only some of these mechanisms from the extensive literature. In
streptozotocin (STZ)-induced diabetic rats, the left ventricle has a
biphasic pattern of sensory innervation in different stages of diabetes
(Bakovic et al., 2018). In early diabetes mellitus (between 2 weeks and
2 months after induction) an increase of neurofilament 200 kDa
(NF200, a marker for sensory myelinated neurons) and tyrosine-
hydroxylase (TH, marker of the sympathetic fibres) protein content
could be found in the left ventricular wall and in the interventricular
septum compared to control animals. While in the later stages
(between 6 and 12 months post-diabetes mellitus induction), the
above increases in the density of NF200 and TH immunoreactive
fibres have disappeared (Bakovic et al., 2018). In experimental diet
and STZ-induced diabetic model of rats, the sensory nerve impairment
(validated by tail flick latency test) significantly exaggerated myocar-
dial damages and increased the infarct size and myocyte apoptosis
(Li et al., 2017). Using STZ-induced diabetes in Male Sprague–Dawley
rats (Xuan et al., 2015), analysis of heart rate variability revealed a rel-
ative sympathetic hyperinnervation, which was accompínied with
increased ventricular arrhythmogenesis in the diabetic group as com-
pared to the control. However, looking at the immunohistochemistry
of choline O-acetyltransferase (ChAT) and L-tyrosine hydroxylase
(TH) positive nerve fibres as marker of parasympathetic and sympa-
thetic nerve respectively, short-term diabetes (3 months) resulted in
myocardial parasympathetic denervation without significant sympa-
thetic neural damage. By 6 months, sympatho-parasympathetic imbal-
ance had further developed. This time-dependent neural denervation
and heterogeneous innervation might cause relatively sympathetic
hyperinnervation, which increases ventricular arrhythmogenesis.
Interestingly in the prediabetic state of a diabetic rat model induced
by the combination of low-dose STZ and high-fat diet, it was shown
that the deterioration of diastolic function and sensory neuropathy
occurs earlier than the manifestation of diabetes (Koncsos
et al., 2016).
6.3 | Secondary neuropathies: Autoimmune
disorders
Most peripheral neuropathies accompanying autoimmune disorders
affect the limbs, however cardiac involvement can also be present
(Burakgazi & AlMahameed, 2016).
10 BENCSIK ET AL.
Systemic lupus erythematosus (SLE) is a complex heterogeneous
autoimmune disease characterized by autoantibody production and
immune complex deposition followed by damage to target tissues.
Chen, Tang, Zhu, and Xu (2016) found in their meta-analysis of
22 studies that patients with SLE develop left ventricular systolic and
diastolic dysfunction. Cardiac MR imaging mainly shows vasculitis,
myocarditis, and myocardial infarction in patients with SLE
(Mavrogeni et al., 2018). Accordingly, many studies reported that SLE
patients have much higher cardiovascular risk and higher in-hospital
mortality rate after acute myocardial infarction (Ke et al., 2019). SLE
may lead to sensory neuropathy, which is limited to the CNS or the
optic nerve (Dammacco, 2018), but according to our knowledge there
are no available data on sensory neuropathy affecting cardiac nerves
in SLE patients. Although there are several animal models, none of
them are relevant to the association between sensory neuropathy and
the heart.
Rheumatoid arthritis (RA) is a chronic autoimmune disease leading
to synovial inflammation and resulting in swelling and pain in and
around the joints. Rheumatoid arthritis also affects the cardiovascular
system including myocardium. Conduction disturbances and arrhyth-
mias could be signs of cardiac involvement of sensory nerve impair-
ment due to rheumatic diseases (Seferovic et al., 2006). Buleu, Sirbu,
Caraba and Dragan, (2019) found that cardiac manifestations of sys-
temic inflammation can occur frequently with different prevalence in
rheumatic diseases and it can affect the myocardium, cardiac valves,
pericardium, conduction system and arterial vasculature. However,
the presence of sensory neuropathy was not tested in any of the
above-mentioned studies with rheumatoid arthritis patients. Never-
theless, a recent case report showed a silent myocardial infarction in a
rheumatoid arthritis patient with diagnosed cardiac autonomic neu-
ropathy (Unnikrishnan, Jacob, Anthony Diaz, & Lederman, 2016). Ani-
mal models for rheumatoid arthritis include induced arthritis models,
such as genetically manipulated, the spontaneous arthritis models,
such as the TNF-α-transgenic mouse, K/BxN mouse and the collagen-
induced arthritis, such as collagen-antibody-induced arthritis,
zymosan-induced arthritis and the methylated BSA model
(Choudhary, Bhatt, & Prabhavalkar, 2018). In the animal models of
rheumatoid arthritis, sensory neuropathy in the heart has not been
investigated. The effect of long-term inflammation in the collagen
antibody-induced arthritis mouse model, Pironti et al. showed that
there was long-term consequences of molecular remodelling on the
contractile function of the heart. They found that rheumatoid arthritis
contributes to the development of heart failure, cardiomyopathy and
contractile dysfunction, fibrosis and reduced left ventricular fractional
shortening compared to control (Pironti et al., 2018).
Sjögren's syndrome is a chronic autoimmune disorder that affects
mainly the lacrimal and salivary glands and could cause peripheral
neuropathy and dry eye. Signs of cardiovascular autonomic nervous
system dysfunction was detected in majority of patients affecting
heart rate, BP variability, spontaneous baroreflex sensitivity and car-
diovascular reflexes (Kovacs et al., 2004). Primary Sjögren syndrome
may cause severe arteriosclerosis, development of ischaemic heart
disease and occurrence of sudden cardiac death (Inoue et al., 2008).
Like any other complex human disease, Sjögren's syndrome has no
single animal model which could replicate all aspects of the disease.
Therefore, animal models of Sjögren's syndrome have a huge variabil-
ity as there are spontaneous, genetically engineered and experimen-
tally induced models. The autoimmune regulator (Aire) gene-deficient
mice develop spontaneous, CD4+ T cell-mediated exocrinopathy,
which leads to dry eye that is associated with loss of nerves innervat-
ing the cornea and lacrimal gland. Peripheral neuropathies characteris-
tic for Sjögren's syndrome is tightly linked with the underlying
immunopathological mechanism, and Aire−/− mice provide an excel-
lent tool to explore the interplay between Sjögren's syndrome associ-
ated immunopathology and peripheral neuropathy (Chen et al., 2017).
However, cardiac effects in the above mice model have not been
investigated yet.
6.4 | Secondary neuropathies: Drug-induced and
toxic neuropathies
There are several xenobiotics including drugs, toxins and chemicals,
which may cause sensory neuropathy. A detailed list of these com-
pounds is available in a recent review by Karam and Dyck, who distin-
guished different appearance and manifestation of neuropathies
caused by the such compounds (Karam & Dyck, 2015). Since treat-
ment with the specific compound leads to the same deleterious effect
on sensory nerves as in humans, detailed descriptions of these models
would exceed the scope of the present review.
Anticancer drugs including taxanes, platinum derivatives and
vinca alkaloids possess the most abundant literature related to neu-
ropathies, which are predominantly sensory in type. Indeed, morpho-
logical studies show degenerative alterations in cutaneous C-fibre
innervation following the administration of paclitaxel, vincristine
(Siau, Xiao, & Bennett, 2006) and anthracyclines
(adriamycin/doxorubicin; Boros et al., 2016) similar to that seen after
capsaicin treatment (Dux, Sann, Schemann, & Jancso, 1999).
Bortezomib, a proteasome inhibitor used for the treatment of multiple
myeloma and thalidomide, an immunomodulatory drug against Myco-
bacterium subspecies, are also able to evoke severe sensory neuropa-
thy characterized by painful paraesthesia due to the peripheral loss of
large myelinated fibres (Karam & Dyck, 2015). In contrast to
anthracyclins or taxanes, only the occasional but not severe or signifi-
cant cardiotoxicity has been shown to be caused by either bortezomib
or thalidomide (Reneau et al., 2017).
Among cardiovascular drugs, the cholesterol-lowering statins
(simvastatin, pravastatin and fluvastatin) seem to have significant risk
factors for the development of primary sensory neuropathy (Jones
et al., 2019). However, only a few clinical trials or meta-analysis stud-
ies have identified statin-related peripheral neuropathy, which was
predominantly of the sensory type (summarized in the review of Jones
et al., 2019), and the mechanism is also largely unknown. It is sup-
posed to be associated with energy depletion of neurons due to
decreased ubiquinone synthesis. However, their well-known cardi-
oprotective and anti-atherosclerotic effects are far outweigh the
BENCSIK ET AL. 11
sporadic appearance of statin-derived sensory neuropathy. Also, the
anti-arrhythmic drug, amiodarone, in high dose and over a long
duration has a risk of causing sensory and motor deficits in patients
(Jones et al., 2019).
There are a couple of antibiotics (nitrofurantoin, linezolid, etham-
butol and chloramphenicol) which develop neuropathy during chronic
application. However, most of them induce only a slight sensory
rather than other types of neuropathies (see for review Karam &
Dyck, 2015). The one exception is the group of antiretroviral agents
(nucleoside analogue reverse transcriptase inhibitors e.g. zalcitabine
and stavudine), which may lead to severe distal sensory neuropathy
accompanied by neuropathic pain.
Beyond medical treatments, it is worth mentioning that agricul-
turally or industrially used compounds, such as organophosphates and
vacor (pyrinuron), as well as dimethylaminopropionitrile (Staff &
Windebank, 2014), may lead to the development of severe sensory
neuropathy (see for review Karam & Dyck, 2015). However, their car-
diac effects due to sensory neuropathy are hard to distinguish from
their severe systemic actions, for example increased vagal tone due to
cholinesterase inhibition (organophosphates) or hyperglycaemic
ketoacidosis in case of vacor.
It is well known that chronic ethanol abuse leads to sensory and
also motor neuropathy. Specifically, alcohol-related neuropathy pre-
sents with a slowly progressive, sensory-dominant symptoms, while
thiamine deficiency causes an acutely progressive (<1 month in 56%),
primarily motor-dominant features with the loss of ambulation (Koike
et al., 2003). Moreover, it has been shown that ethanol intoxication-
induced sensory neuropathy alone does not lead to heart failure, only
when alcohol abuse was combined with vitamin B1 (thiamine) defi-
ciency (Koike et al., 2003). However, chronic ethanol abuse leads to
enhanced cardiac mitochondrial oxidative stress accompanied with
myocardial dysfunction, as demonstrated recently by Matyas
et al. (2016) using a mouse model of chronic plus binge alcohol
feeding-induced ethanol intoxication. Thus, direct cardiac effects of
ethanol intoxication show a more pronounced cardiotoxicity than that
of indirectly caused by sensory nerve injury.
There are several further toxins including inorganic compounds as
thallium, arsenic or lead, as well as biotoxins such as tetrodotoxin,
diphtheria or tick paralysis toxin, which may contribute to the devel-
opment of sensory neuropathy. However, they cause development of
complex multi-organ injuries including the heart. Therefore, their dis-
cussion would exceed the scope of the present review and are dis-
cussed in detail elsewhere (Karam & Dyck, 2015).
It is not known how sensory neuropathy may contribute to the
“hidden cardiotoxicity” (a novel concept, i.e. cardiotoxicity seen only
in the diseased heart) of some drugs and toxins, including, for exam-
ple, statins (Ferdinandy et al., 2019).
6.5 | Secondary neuropathies: Vitamin and
cofactor deficiencies
Beyond the most common metabolic disorders such as diabetes and
the toxic effects of certain drugs, several other factors or diseases can
lead to the development of sensory neuropathies. As we previously
discussed in ethanol intoxication section, thiamine (vitamin B1) defi-
ciency is also an aetiological factor for sensory (and motor) neuropa-
thy accompanied with cardiovascular complications, based on the
results of a study where over 2/3 of the enrolled patients with vitamin
B1 deficiency developed signs of heart failure (Koike et al., 2003). The
lack of cobalamin (vitamin B12) may cause primary sensory demyelin-
ation (Steiner, Kidron, Soffer, Wirguin, & Abramsky, 1988).
Puntambekar, Basha, Zak, and Madhavan (2009) reported a case of a
patient with vitamin B12 deficiency developing atrial fibrillation and
sinus tachycardia due to sensory and autonomic neural dysfunction.
However, other publications related to cobalamin deficiency do not
refer to any cardiovascular symptoms. It has been shown that isolated
vitamin E deficiency may lead to peripheral neuropathy, but it was not
accompanied by ECG alterations (Puri, Chaudhry, Tatke, &
Prakash, 2005). In contrary, excessive intake of pyridoxin (vitamin B6)
also resulted in similar sensory neuropathy both in patients (Gdynia
et al., 2008) and in a rat model (Windebank, Low, Blexrud,
Schmelzer, & Schaumburg, 1985), but any signs of cardiac dysfunc-
tions were not measured.
6.6 | Secondary neuropathies: Others
Infections by human immunodeficiency virus (Karpul, McIntyre, van
Schaik, Breen, & Heckmann, 2019), hepatitis C (Yoon et al., 2011) or
Zika virus (Medina & Medina-Montoya, 2017), as well as alteration of
hormonal status such as hypothyroidism (Eslamian et al., 2011) have
been shown to lead to sensory neuropathy. Guillain–Barré syndrome
is a rare disease when the immune system starts to attack the nervous
system primarily causing acute inflammatory demyelinating poly-
radiculoneuropathy (Burakgazi & AlMahameed, 2016). The autonomic
and cardiovascular involvement in Guillain–Barré syndrome involve
mainly the autonomic fibres (Burakgazi & AlMahameed, 2016). How-
ever, in all the above-mentioned conditions, the aetiological role of
sensory dysfunction in the cardiovascular complications is not obvi-
ous; cardiac pathology develops directly in response to the primary
disease (i.e. infections or hormonal disorders).
7 | SENSORY NEUROPATHY AND ITS
PRECLINICAL MODELS
Sensory neuropathy denotes diseases of the sensory nerves in which
either the axon or the myelin-forming cells are dysfunctional due to
metabolic, toxic, infectious or genetic causes, which results in several
clinical symptoms like hyperalgesia, allodynia or the opposite, reduced
ability to sense pain or extreme temperatures and paraesthesias
(Ochoa, 1995). There are plenty of pathologies leading to sensory
neuropathies (see more details on animal models above), although iso-
lated sensory neuropathy can be achieved experimentally by the
systemic application of capsaicin or its ultrapotent analogue,
resiniferatoxin.
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Neurochemical and histochemical studies have demonstrated a
remarkable reductions in substance P and CGRP levels in sensory
nerves (Gamse et al., 1981), including cardiac nerves (Ferdinandy
et al., 1997), after systemic capsaicin treatment, also referred to as
capsaicin desensitization or selective sensory chemodenervation (Dux
et al., 1999). This is a unique and selective experimental tool that is
used to mimic sensory neuropathies induced by metabolic disorders
or drug treatments allows the investigation of the role of peptidergic
capsaicin-sensitive sensory nerves in a variety of pathophysiological
mechanisms.
Resiniferatoxin is an ultrapotent analogue of capsaicin, which also
selectively acts on primary sensory neurons resulting in ultrastructural
alterations and CGRP depletion. Resiniferatoxin does not change
heart rate or BP nor does it provoke the pulmonary chemoreflex in
the rat, the latter is the main limiting factor in capsaicin treatment
(Szolcsanyi, Szallasi, Szallasi, Joo, & Blumberg, 1990). This suggests a
further advantage in using resiniferatoxin to investigate capsaicin-
sensitive neural pathways (Szolcsanyi et al., 1990). In isolated rat car-
diac mitochondria, resiniferatoxin caused concentration-dependent
decrease in oxygen consumption and lowered mitochondrial mem-
brane potential (Athanasiou et al., 2007), since TRPV1 channels are
located in intracellular and mitochondrial membranes as well.
Resiniferatoxin application has beneficial effects on cardiac and
autonomic dysfunction in rats with myocardial infarction-induced
chronic heart failure. Epicardial application of resiniferatoxin in rats
9–11 weeks after the myocardial ischaemia interrupts already acti-
vated cardiac sympathetic afferents, thereby reducing a major source
of sympatho-excitation in chronic heart failure. This experimental
result shows the importance and therapeutic potential of targeted
desensitization of cardiac sympathetic afferent reflex in ventricular
remodelling after myocardial infarction (Wang, Wang, Cornish,
Rozanski, & Zucker, 2014). Furthermore, epicardial resiniferatoxin
application lowered diastolic BP both at daytime and night-time with
less effect on systolic BP in chronic heart failure rats compared to the
sham group. Cardiac sympathetic afferent reflex activation physiologi-
cally causes significant increase in cardiac contractility and output
(Wang, Rozanski, & Zucker, 2017). In the rat model of transverse aor-
tic constriction-induced cardiac remodelling resiniferatoxin pre-
treatment improved haemodynamic data (reduced left ventricular
end-diastolic pressure) and also prevented cardiac hypertrophy, fibro-
sis and apoptosis. Focal chemo-ablation of TRPV1+ neurons in the spi-
nal cord protects the heart from pressure overload-induced cardiac
remodelling and cardiac dysfunction, which could be a promising
novel therapeutic treatment against cardiac hypertrophy and diastolic
dysfunction (Wang, Wu, et al., 2019).
8 | SIMULTANEOUS THERAPEUTIC
OPTIONS FOR THE ISCHAEMIC HEART IN
SENSORY NEUROPATHY
There is no available drug treatment for indications of sensory neurop-
athy approved by the Federal Drug Agency or the European
Medicines Agency. In most cases, the treatment of sensory neuropa-
thy consists of the symptomatic pharmacological treatment of neuro-
pathic pain related to diabetes- or chemotherapy-induced neuropathy.
Gwathmey and Pearson (2019) summarized their findings on the
above therapies and classified them in three levels (A to C, where A is
the most preferable) according to the strength of evidence for effi-
cacy. According to the above-mentioned review, at Level A, the treat-
ment of neuropathic pain can be treated with the following drugs,
gabapentin, pregabalin, venlafaxine, duloxetine, tricyclic antidepres-
sants (e.g. amitriptyline), tramadol and oxycodone, at Level B
valproate, dextromethorphan, capsaicin and botulinum toxin should
be used, while at Level C carbamazepine. Since there is no causal
treatment for sensory neuropathy, there is an utmost need for novel
therapeutic targets focusing on preservation of physiological functions
of nerves/neurons and cardiac myocytes simultaneously. In
Clinicaltrials.gov database, 56 studies can be found by the term “sen-
sory neuropathy.” In 20 of these studies, the study protocol includes
pharmacological approaches to improve the primary disease or to alle-
viate pain symptoms, however none of them relates to
cardioprotection.
One of the most promising novel drug candidates in experimen-
tal phase is BGP-15 that could improve hereditary sensory and auto-
nomic neuropathy Type III (HSAN III, also called FD). FD is a genetic
disorder caused by a single base substitution in the IKBKAP gene
resulting in disrupt development of the peripheral nervous system,
which also affects sensory nerves. This condition can have fatal con-
sequences resulting from functional and electrophysiological instabil-
ity, respiratory dysfunction and/or sudden death during sleep
(Norcliffe-Kaufmann, Slaugenhaupt, & Kaufmann, 2017). Ohlen et al.
(2017) demonstrated by using an Ikbkap/Elp1 conditional-knockout
mouse model that daily injections of BGP-15 (O-(3-piperidino-
2-hydroxy-1-propyl)nicotinic amidoxime), a cardioprotective com-
pound developed by a Hungarian biotech company in late 1990s,
significantly improved cardiac innervation and prevented the death
of Ikbkap−/− neurons (Table 2). BGP-15 was basically developed
against PARP as an insulin sensitizer drug, but it has been shown
that it protects isolated rat hearts against ischaemia/reperfusion
injury (Szabados, Literati-Nagy, Farkas, & Sumegi, 2000). Recently,
BGP-15 has been shown to prevent the impairment of sensory
nerves conduction velocity in cisplatin- or taxol-induced peripheral
neuropathy in rats (Bárdos et al., 2003). More recently, BGP-15 was
applied against diabetic cardiomyopathy in a spontaneous diabetic
Goto-Kakizaki rat model (Bombicz et al., 2019). The BGP-
15-treatment considerably enhanced diastolic function and improved
Tei-index in Goto-Kakizaki rats, by affecting the
SERCA/phospholamban pathway (Bombicz et al., 2019). Beneficial
effects of BGP-15 have been shown in models of diabetes, muscular
dystrophy, HSAN and also in heart failure, where it has affected
chaperones, contractile and mitochondrial proteins, as well as SERCA
(Gehrig et al., 2012; Ohlen et al., 2017; Sapra et al., 2014).
To find efficacious treatment for diabetes mellitus-associated
sensory neuropathy is critical since the incidence of diabetes and
thereby the appearance of sensory neuropathy is rapidly increasing
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worldwide. As we discussed above, cardiovascular autonomic neurop-
athy is a frequent complication of diabetes. It was shown that there is
a prognostic value of cardiovascular autonomic neuropathy for cardio-
vascular mortality and morbidity in both Type 1 and Type 2 diabetes
(Spallone, 2019). Besides the association with both fatal- and non-
fatal cardiovascular events, cardiovascular autonomic neuropathy also
showed strong correlation with glycaemic control (Pop-Busui
et al., 2017). Prevention and existing treatment of cardiovascular
autonomic neuropathy include lifestyle modifications and strict con-
trol of blood glucose level (involving oral antidiabetic drugs or insulin
therapy if needed). However, the pathogenesis-based pharmacological
treatment consists of antioxidant therapy such as α-lipoic acid and
vitamin E (Table 2; Ziegler et al., 1997). α-Lipoic acid has been recently
shown to reduce myocardial infarct size when administered 30 min
before coronary occlusion in rats (Deng et al., 2013). Most recently, α-
tocopherol, the strongest antioxidant form of vitamin E, applied 2 hr
prior to 60-min coronary occlusion, immediately after reperfusion and
twice per day for three consecutive days in mice, has been shown to
decrease infarct size and improve left ventricular function 4 weeks
after the development of acute myocardial infarction (Wallert
et al., 2019). As an alternative option for improving sensory function
in diabetic patients suffering from cardiovascular autonomic neuropa-
thy is the inhibitors of aldose reductase (Table 2; e.g. ranirestat,
zopolrestat and epalrestat). Ranirestat and zopolrestat are already
tested in clinical phases and have been shown to improve sensory
nerve conduction velocity in both Type 1 and Type 2 diabetic patients
(Sekiguchi et al., 2019) and to stabilize or partially reverse left ventric-
ular abnormalities in cardiovascular autonomic neuropathy patients
(Fisher & Tahrani, 2017). Moreover, non-selective inhibition of aldose
reductase by suldinac has been shown to reduce myocardial infarct
size in normal and also in STZ-induced diabetic rats (Annapurna,
Challa, Prakash, & Viswanath, 2008).
Recently, a novel cardiovascular and anti-diabetic/anti-
neuropathic indication for phosphodiesterase type 5 (PDE5) inhibi-
tors (e.g. sildenafil, tadalafil and vardenafil) have been intensively
studied. PDE5 selectively hydrolyses the second messenger cGMP,
thereby regulating its intracellular concentrations. Dysregulation of
the cGMP-dependent pathway plays a crucial role in various cardio-
vascular diseases such as erectile dysfunction and pulmonary hyper-
tension (Tsai & Kass, 2009). Tadalafil has previously been shown to
reduce infarct size in both normal and Type 2 diabetic rats and mice
(Table 2; reviewed in Das, Durrant, Salloum, Xi, & Kukreja, 2015). Fur-
thermore, recently, it has been shown that tadalafil improves sensory
nerve conduction velocity in Type 2 diabetic db/db mice (Wang
et al., 2016). Long-term administration of vardenafil led to effective
prevention of developing HFpEF characterized by increased myocar-
dial stiffness and worsened diastolic function in Type 2 diabetic
Zucker diabetic fatty rats. In the same study, vardenafil treatment also
reduced the pathophysiological features of diabetes-associated car-
diomyopathy and restored the activity of cGMP–PKG axis by increas-
ing myocardial and plasma cGMP levels (Matyas et al., 2017). Thus,
PDE5 inhibition may simultaneously reduce myocardial infarct size,
achieve improvement in Type 2 diabetes, one of the major causes of
sensory neuropathy and recovers myocardium from HFpEF. However,
the proportion of diabetes-induced sensory neuropathy in the devel-
opment of diabetic HFpEF still remains the subject of further
investigations.
9 | CONCLUSIONS AND FUTURE
PERSPECTIVES
Abundant data from literature demonstrate that sensory nerves play
pivotal roles in the physiological and pathological of the heart.
Despite, in the last decades, research starting to focus on the role of
cardiac innervation in cardiac pathologies and cardioprotection, little
is still known on the mechanism and the effect of sensory neuropathy
on cardiovascular morbidities, especially ischaemic heart disease and
cardioprotection. Nevertheless, several promising therapeutic
approaches have emerged recently which may have beneficial actions
on myocardial ischaemic injury and simultaneously improve the symp-
toms of sensory neuropathy of different aetiologies.
9.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked in
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander et al., 2019).
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